DDInter596 DDInter1293
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Doxorubicin {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Nilotinib
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Nilotinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) KIT
KIT {u} (Gene) is bound by {v} (Compound) Nilotinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) ADO
ADO {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) IL1B
IL1B {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) CDC20
CDC20 {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Doxorubicin {u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene) TOP2A
TOP2A {u} (Gene) is downregulated by {v} (Compound) Nilotinib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Lymphopenia
Lymphopenia {u} (Side Effect) is caused by {v} (Compound) Nilotinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) EPHB2
EPHB2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Nilotinib
Doxorubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Nilotinib (Compound)
Doxorubicin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Nilotinib (Compound)
Doxorubicin (Compound) upregulates KIT (Gene) and KIT (Gene) is bound by Nilotinib (Compound)
Doxorubicin (Compound) downregulates ADO (Gene) and ADO (Gene) is upregulated by Nilotinib (Compound)
Doxorubicin (Compound) upregulates IL1B (Gene) and IL1B (Gene) is upregulated by Nilotinib (Compound)
Doxorubicin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Nilotinib (Compound)
Doxorubicin (Compound) binds TOP2A (Gene) and Doxorubicin (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is downregulated by Nilotinib (Compound)
Doxorubicin (Compound) causes Lymphopenia (Side Effect) and Lymphopenia (Side Effect) is caused by Nilotinib (Compound)
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may lead to a major life threatening interaction when taken with Nilotinib
Doxorubicin (Compound) upregulates EPHB2 (Gene) and EPHB2 (Gene) is bound by Nilotinib (Compound) and EPHB2 (Gene) is upregulated by Nilotinib (Compound)